Therapeutic Benefit of Top-Selling Oncology Drugs in Medicare.
作者信息
Wang Stephanie, Egilman Alexander C, Hahn Georg, Kesselheim Aaron S
机构信息
Harvard College, Cambridge, Massachusetts.
Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
出版信息
JAMA Netw Open. 2025 Apr 1;8(4):e253323. doi: 10.1001/jamanetworkopen.2025.3323.
Abstract
摘要
相似文献
1
Therapeutic Benefit of Top-Selling Oncology Drugs in Medicare.医疗保险中畅销肿瘤药物的治疗效益。
JAMA Netw Open. 2025 Apr 1;8(4):e253323. doi: 10.1001/jamanetworkopen.2025.3323.
2
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.增加了医疗保险中最畅销的品牌药物的治疗效益。
JAMA. 2023 Apr 18;329(15):1283-1289. doi: 10.1001/jama.2023.4034.
3
Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.加拿大肿瘤药物卫生技术评估与价格谈判的及时性
Clinicoecon Outcomes Res. 2024 May 25;16:437-445. doi: 10.2147/CEOR.S462872. eCollection 2024.
4
Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.使用附加治疗效益和治疗参考定价在美国医疗保险药品价格谈判中的节省估计。
Value Health. 2023 Nov;26(11):1618-1624. doi: 10.1016/j.jval.2023.08.004. Epub 2023 Sep 7.
5
Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.纳入医保价格谈判的药品价格基准及其治疗替代方案。
J Manag Care Spec Pharm. 2024 Aug;30(8):762-772. doi: 10.18553/jmcp.2024.24153. Epub 2024 Jun 21.
6
Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act.《降低通胀法案》后的医疗保险价格谈判与药物创新
Nat Biotechnol. 2024 Mar;42(3):406-412. doi: 10.1038/s41587-023-02096-w. Epub 2024 Jan 31.
7
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.2022年《降低通胀法案》下模拟的医疗保险药品价格谈判
JAMA Health Forum. 2023 Jan 6;4(1):e225218. doi: 10.1001/jamahealthforum.2022.5218.
8
A Comparative Analysis of International Drug Price Negotiation Frameworks: An Interview Study of Key Stakeholders.国际药品价格谈判框架的比较分析：关键利益相关者访谈研究
Milbank Q. 2024 Dec;102(4):1004-1031. doi: 10.1111/1468-0009.12714. Epub 2024 Sep 17.
9
The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health.支付意愿阈值对肿瘤药物降价建议的影响：加拿大卫生药品和技术局所做评估综述
J Comp Eff Res. 2024 May;13(5):e230178. doi: 10.57264/cer-2023-0178. Epub 2024 Apr 3.
10
Examining Opportunities to Increase Savings From Medicare Price Negotiations.审视增加 Medicare 价格谈判节省机会。
JAMA Intern Med. 2023 Jun 1;183(6):581-588. doi: 10.1001/jamainternmed.2023.0763.
本文引用的文献
1
The cancer premium - explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional study.癌症药物溢价——在美国、德国和瑞士，基于疗效和流行病学终点解释癌症药物与非癌症药物价格差异的横断面研究
EClinicalMedicine. 2023 Jul 13;61:102087. doi: 10.1016/j.eclinm.2023.102087. eCollection 2023 Jul.
2
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.增加了医疗保险中最畅销的品牌药物的治疗效益。
JAMA. 2023 Apr 18;329(15):1283-1289. doi: 10.1001/jama.2023.4034.
3
Estimating Rebates and Other Discounts Received by Medicare Part D.估算医疗保险处方药部分（Medicare Part D）收到的回扣和其他折扣
JAMA Health Forum. 2021 Jun 4;2(6):e210626. doi: 10.1001/jamahealthforum.2021.0626.
4
Assessment of Out-of-Pocket Costs With Rebate Pass-through for Brand-name Cancer Drugs Under Medicare Part D.评估医疗保险部分 D 下品牌癌症药物通过回扣传递的自付费用。
JAMA Oncol. 2022 Jan 1;8(1):155-156. doi: 10.1001/jamaoncol.2021.5433.
5
Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018.2012-2018 年具有新仿制药或生物类似药竞争的药品市场独占期长度。
Clin Pharmacol Ther. 2021 Feb;109(2):367-371. doi: 10.1002/cpt.1983. Epub 2020 Aug 7.
Zotero 插件